Evidence map›Paper›PMID 39653946›Full record

ArticleAnnals of surgical oncology2025

ASO Author Reflections: Nodal Recurrence Is Rare in Patients with cN+/ycN0 Breast Cancer after Neoadjuvant Chemotherapy Regardless of the Extent of Axillary Surgery or Nodal Pathology in the NEOSENTITURK-Trials MF18-02/18-03 Provided Regional Nodal Irradiation Is Administered.

Neslihan Cabioglu, Hasan Karanlik, Abdullah Igci, M Muslumanoglu, Mehmet Ali Gulcelik, Cihan Uras, H Belma Kocer, Atilla Soran, Kamuran Ibis, Vahit Ozmen

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04250129 (IS SENTINEL LYMPH NODE BIOPSY WITH RADIOTHERAPY ALONE WITHOUT AXILLARY LYMPH NODE DISSECTION SAFE FOLLOWING NEOADJUVANT CHEMOTHERAPY IN INITIALLY CLINICALLY AXILLA POSITIVE PATIENTS), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04250129 unknown statusnot on this map

Is sentinel lymph node biopsy with radiotherapy alone without axillary lymph node dissection safe following neoadjuvant chemotherapy in initially clinically axilla positive patients: neosentiturk-trial/mf-18-03

TypeobservationalSponsorFederation of Breast Diseases SocietiesRan2018 to 2023Enrolled500ConditionsSentinel Lymph Node
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Neslihan CabiogluBreast Unit, Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye. neslicab@yahoo.com.
Hasan KaranlikDepartment of Surgical Oncology, Institute of Oncology, Istanbul University, Istanbul, Türkiye.
Abdullah IgciBreast Unit, Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
M MuslumanogluBreast Unit, Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Mehmet Ali GulcelikDepartment of Surgical Oncology, Gulhane Faculty of Medicine, Health Sciences University, Ankara, Türkiye.
Cihan UrasDepartment of General Surgery, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Türkiye.
H Belma KocerDepartment of General Surgery, Faculty of Medicine, Sakarya University, Sakarya, Türkiye.
Atilla SoranDepartment of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Kamuran IbisDepartment of Radiation Oncology, Institute of Oncology, Istanbul University, Istanbul, Türkiye.
Vahit OzmenBreast Unit, Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combined analysis of the retrospective multicentre and prospective multicenter cohort registry trial NEOSENTITURK MF18-02/18-03 (NCT04250129) investigated the outcomes and factors associated with recurrence in patients with cT1-4N1-3M0 who underwent a succesful sentinel lymph node biopsy or targeted axillary dissection (n = 1470), with or without axillary lymph node dissection (n = 937) after neoadjuvant chemotherapy. The present large registry data suggest that axillary recurrences (AR) can be detected at exceedingly low rates (< 0.5%) within 3 years after surgery. This is regardless of the extent of axillary surgery or nodal pathology, provided that regional nodal irradiation is administered. Factors associated with increased risk for AR included age under 45 years, nonpathologic complete response (non-pCR) in the breast, and nonluminal pathology. Similarly, having cT3-4, a non-pCR in the breast or axilla, and nonluminal pathology were identified as poor prognostic factors.

Indexed as

AxillaBreast NeoplasmsChemotherapy, AdjuvantLymph NodesNeoadjuvant TherapyNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHumansLymphatic MetastasisLymph Node ExcisionMiddle AgedPrognosisProspective StudiesRegistriesAxillary lymph node dissectionBreast cancer recurrenceNeoadjuvant chemotherapyNodal recurrenceNonluminal pathologyRegional nodal irradiationSentinel lymph node biopsySurvivalYoung age

Identifiers

PMID39653946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.